Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit

May 5, 2021

The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D. In this conversation with Alicia Morgans, MD, MPH. Dr. de Witt highlights the posthoc analysis completed in a large real-world dataset comparing characteristics of patients receiving cabazitaxel after docetaxel and one androgen-signaling-targeted inhibitor with the CARD-eligible population. From 12,000 patients with mCRPC who had received at least one line of treatment for their metastatic CRPC disease, 450 patients who matched the CARD criteria were selected. Dr. de Witt highlights key findings from this real-world dataset and the pair discusses how it relates to everyday clinical practice.

Biographies:

Ronald de Wit, MD, Ph.D., Professor, Department Medical Oncology, Division Lead Genito-Urinary Clinical Research, Erasmus University Medical Center, Rotterdam, the Netherlands.

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.


Read the Full Video Transcript